Gonadotrophin‐releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi‐center randomized trial

Granese R, Roberta Granese, Antonino Perino, A Perino, Gloria Calagna, Glória Calagna, Saitta S, Salvatore Saitta, Pasquale De Franciscis, Nicola Colacurci, Colacurci N, Onofrio Triolo, Triolo O, Gaspare Cucinella
Acta obstetricia et gynecologica Scandinavica · 2015 · vol. 94(6) , pp. 637–645 · doi:10.1111/aogs.12633 · PMID:25761587 · W2042757069
article OA: green CC0 ⤵ 48 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

Dienogest plus estradiol valerate and gonadotrophin-releasing hormone analogue were equally effective in preventing endometriosis-related pain recurrence and improving quality of life for nine months post-surgery.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To evaluate the efficacy of dienogest + estradiol valerate (E2V) and gonadotrophin-releasing hormone analogue (GnRH-a) in reducing recurrence of pain in patients with chronic pelvic pain due to laparoscopically diagnosed and treated endometriosis. DESIGN: Multi-center, prospective, randomized study. SETTING: Three university departments of obstetrics and gynecology in Italy. POPULATION: Seventy-eight women who underwent laparoscopic surgery for endometriosis combined with chronic pelvic pain. METHODS: Post-operative administration of dienogest + E2V for 9 months (group 1) or GnRH-a monthly for 6 months (group 2). MAIN OUTCOME MEASURES: A visual analogue scale was used to test intensity of pain before laparoscopic surgery at 3, 6 and 9 months of follow up. A questionnaire to investigate quality of life was administered before surgery and at 9 months of follow up. RESULTS: The visual analogue scale score did not show any significant differences between the two groups (p = 0.417). The questionnaire showed an increase of scores for all women compared with pre-surgery values, demonstrating a marked improvement in quality of life and health-related satisfaction with both treatments. No significant differences were found between the groups. The rate of apparent endometriosis recurrence was 10.8% in group 1 and 13.7% in group 2 (p = 0.962). CONCLUSION: Both therapies seemed equally efficacious in preventing endometriosis-related chronic pelvic pain recurrence in the first 9 months of follow-up.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Estradiol Gonadotropin-Releasing Hormone Laparoscopy Nandrolone Pelvic Pain Pelvic Pain Adolescent Adult Drug Combinations Endometriosis Estradiol Estradiol Female Gonadotropin-Releasing Hormone Humans Italy Middle Aged Nandrolone Nandrolone

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (43)

Cited by (49)

Source provenance

europepmc
last seen: 2026-09-30T06:18:36.089610+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:58.238279+00:00
License: CC0 · commercial use OK